Status | Study |
Enrolling by invitation |
Study Name: Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Condition: Duchenne Muscular Dystrophy Date: 2017-01-30 Interventions: Drug: Vamorolone 0.25 mg/day/day |
Recruiting |
Study Name: An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy Condition: Duchenne Muscular Dystrophy Date: 2016-09-14 Interventions: Biological: PF-06252616 Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their m |
Recruiting |
Study Name: An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Condition: Duchenne Muscular Dystrophy Date: 2016-04-28 Interventions: Drug: Vamorolone 0.25 mg/day/day |
Recruiting |
Study Name: A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Condition: Duchenne Muscular Dystrophy Date: 2016-04-28 Interventions: Drug: Vamorolone 0.25 mg/kg/day |
Recruiting |
Study Name: Rimeporide in Patients With Duchenne Muscular Dystrophy Condition: Muscular Dystrophy, Duchenne Date: 2016-01-26 Interventions: Drug: Rimeporide Cohort 1: |
Recruiting |
Study Name: Study of DS-5141b in Patients With Duchenne Muscular Dystrophy Condition: Duchenne Muscular Dystrophy Date: 2016-01-26 Interventions: Drug: DS-5141b DS-5141b, Subcutaneous injection |
Withdrawn |
Study Name: Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 Condition: Duchenne Muscular Dystrophy Date: 2015-12-23 Interventions: Biological: rAAVrh74.MCK.GALGT2 |
Active, not recruiting |
Study Name: Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Condition: Duchenne Muscular Dystrophy Date: 2015-08-10 Interventions: Drug: SRP-4045 Drug: Placebo |
Active, not recruiting |
Study Name: Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy Condition: Muscular Dystrophy, Duchenne Date: 2015-04-29 Interventions: Drug: Edasalonexent 67 mg/kg/d |
Recruiting |
Study Name: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy Condition: Duchenne Muscular Dystrophy Date: 2014-11-04 Interventions: Biological: PF-06252616 PF-062 |